In The Press April 26, 2021

Life Sciences Companies Face Heightened Insider Trading Risks and Scrutiny (Program on Corporate Compliance and Enforcement at NYU School of Law)

Insider trading has long been a key enforcement priority for the U.S. Securities and Exchange Commission (SEC) and the U.S. Department of Justice (DOJ). Life sciences companies, along with their executives and directors, have already — and will continue to — face scrutiny arising out of event-driven trading issues relating to COVID-19 diagnostics, treatments, and vaccines share Goodwin’s Litigation partner Annie Railton and associate Courtney Orazio. Read the Program on Corporate Compliance and Enforcement at NYU School of Law byline here.